Should magnesium sulfate and calcium gluconate 10% be routinely added to all parenteral nutrition (PN) admixtures?

Should Magnesium Sulfate and Calcium Gluconate 10% Be Routinely Added to All PN Admixtures?

Yes, both magnesium sulfate and calcium (though preferably NOT calcium gluconate 10% in glass vials) should be routinely incorporated into PN admixtures, as they are essential minerals required for all patients receiving parenteral nutrition, with specific age-based dosing requirements. However, there are critical caveats regarding formulation choice and clinical circumstances that must be considered.

Essential Mineral Requirements

Both calcium and magnesium are mandatory components of complete PN formulations 1. The 2018 ESPGHAN/ESPEN/ESPR/CSPEN guidelines provide specific dosing recommendations:

Magnesium Sulfate Dosing (mmol/kg/day):

• Preterm infants (first days): 0.1-0.2
• Growing premature infants: 0.2-0.3
• Term infants 0-6 months: 0.1-0.2
• Infants 7-12 months: 0.15
• Children 1-18 years: 0.1 1

Calcium Dosing (mmol/kg/day):

• Preterm infants (first days): 0.8-2.0
• Growing premature infants: 1.6-3.5
• Term infants 0-6 months: 0.8-1.5
• Infants 7-12 months: 0.5
• Children 1-18 years: 0.25-0.4 1

The FDA label confirms that in TPN, maintenance magnesium requirements for adults range from 8-24 mEq (1-3 g) daily, and for infants 2-10 mEq (0.25-1.25 g) daily 2.

Critical Formulation Considerations

AVOID Calcium Gluconate in Glass Vials

The guidelines provide a strong recommendation (strong consensus) AGAINST using acidic solutions packaged in glass vials, such as calcium gluconate, due to aluminum contamination 1. Aluminum intake should not exceed 5 mg/kg/day, and glass-packaged calcium gluconate poses significant toxicity risk, particularly in neonates and patients with renal impairment 1.

Instead, use calcium gluconate packaged in polyethylene containers to reduce aluminum contamination 1.

Magnesium Formulation Choice

Magnesium sulfate is the preferred formulation over magnesium chloride 1. Magnesium chloride increases the anion gap and raises the risk of metabolic acidosis, while magnesium sulfate has few compatibility issues 1.

Mandatory Clinical Exceptions

Do NOT routinely add magnesium in these circumstances:

1. Premature newborns whose mothers received magnesium sulfate therapy (for preeclampsia or tocolysis):

   • These infants may have elevated magnesium levels in the first days of life
   • Their low postnatal glomerular filtration rates limit magnesium excretion
   • Magnesium intakes must be limited and adapted to postnatal blood concentrations 1

2. Severe renal insufficiency:

   • Requires dose adjustment and frequent monitoring
   • Maximum dosage considerations apply 2

Compatibility and Safety Considerations

Precipitation Risk

The most critical compatibility issue is calcium-phosphate precipitation, which can cause pulmonary embolism, catheter occlusion, or death 3. To minimize this risk:

• Use organic calcium and phosphate salts (strong recommendation, strong consensus) 1
• Test stability when using upper-range calcium and phosphate concentrations 1
• Follow proper mixing sequence: add calcium to amino acids and glucose first, then add phosphate last 1

Magnesium's Role in Calcium Homeostasis

Magnesium is essential for PTH release and activity. Magnesium deficiency causes both deficient PTH release and peripheral PTH resistance, resulting in hypocalcemia 1. This makes magnesium supplementation critical when providing calcium.

Monitoring Requirements

Both minerals require periodic monitoring during PN 1:

• Blood concentrations of calcium, phosphate, and magnesium
• Urine output and electrolyte excretion
• In preterm infants: adjust until both calcium and phosphate are excreted simultaneously with low urine concentrations (>1 mmol/L) 1

Clinical Consequences of Omission

Failure to provide adequate calcium and phosphorus can result in:

• Severe hypophosphatemia
• Muscle weakness
• Respiratory failure
• Cardiac dysfunction
• Death 1

Magnesium deficiency causes:

• Hypocalcemia (via PTH dysfunction)
• Tetany
• Metabolic complications 1, 2

Practical Algorithm

1. Always include both calcium and magnesium in PN formulations unless specific contraindications exist
2. Use calcium gluconate in polyethylene packaging (never glass vials)
3. Use magnesium sulfate (not magnesium chloride)
4. Dose according to age-specific guidelines [1-1
5. Reduce or delay magnesium if maternal magnesium sulfate exposure occurred
6. Monitor serum levels and adjust based on blood concentrations and renal function
7. Ensure proper mixing sequence to prevent precipitation 3, 4